Body contour changes are commonly seen in prostate and head and neck (H&N) patients undergoing volumetric modulated arc therapy (VMAT) treatments, which may cause a discrepancy between the planned dose and the delivered dose. Dosimetrists, radiation oncologists or medical physicists sometimes are required to visually assess the dosimetric impact of body contour changes and make a judgment call on whether further re-assessment of the plan is needed. However, an intuitive judgment cannot always be made in a timely manner due to the complexity of VMAT plans as well as the complicated forms of body contour changes. This study evaluated the dosimetric effect of body contour changes for prostate and H&N patients to help with clinical decision-making. By analyzing the one-dimensional spatial dose profiles from the original body and the body with different body contour deformations, rules of thumb for dose percentage change and isodose line shift due to body contour changes were ascertained. Moreover, based on dose distribution comparison using three-dimensional gamma analysis, the response of the clinical prostate and H&N VMAT plans to body contour changes was assessed. Within center specific dose deviation tolerances, prostate patients who had less than 2 cm single side body contour change or less than 1 cm uniform body contour change were unlikely to need plan re-assessment; H&N VMAT plans with less than 1 cm uniform body contour change or less than 1 cm shoulder superior-inferior positional change were also unlikely to trigger further evaluation. Dose percentage change and isodose line shift were considered independently from the problem of volume changes in this study, but clinically, both aspects must be considered.
In a conventional planning process, the patient's treatment plan is created based on the anatomy present in the planning computed tomography image set (p-CT), which is typically taken 1 to 2 weeks before the start of radiation therapy. However, during the course of radiation therapy, the patient's anatomy may change in ways that cannot be corrected by image guided radiation therapy (IGRT). Examples for prostate patients include weight change, buttock flex, and abdominal position change. 3, 4 Weight change, tumor shrinkage, and shoulder position variations are commonly seen in head and neck (H&N) patients. [5] [6] [7] [8] [9] As a result, the patient's body contour on the treatment day can deviate from the p-CT and this can be clearly visualized on the volumetric images (e.g., cone-beam CTs) taken on the treatment day.
Essentially, body contour changes can cause changes in beam path length, entry angle, and degree of phantom scatter in a given field. When combined with the high conformality and steep dose gradients generated with VMAT, body contour changes can potentially lead to significant differences between planned and delivered dose. In most cancer centers, it is common for changes in body contour to trigger re-assessment of the plan. 3, [10] [11] [12] Dosimetrists, radiation oncologists or medical physicists need to make a judgment call on further examining the dosimetric impact of body contour changes based on the cone-beam CT (CBCT) taken before treatment as well as the decision to reposition and treat the patient.
In the era of 3D conformal radiation therapy, the effect of body contour changes was commonly estimated by the tissue phantom ratio (TPR) for isocentric setups. For intensity modulated radiation therapy (IMRT), the effect could be approximated by the weighted TPRs for all the fields, which could be done on the fly. However, for
VMAT plans, where the dose rate, gantry speed, and multileaf collimators' movements are changing during the 360°delivery around the patient, it is not intuitive to assess the dosimetric impact of body contour changes. One can perform full dose calculations on the CBCT image sets. This time consuming method can be problematic because of the lack of an accurate electron density conversion curve for CBCT systems and problems associated with image registration between the CBCT and p-CT. On the other hand, the number of patients who can be re-assessed and re-planned is constrained by the limitation of resources in a clinic. Thus, it is important to have some efficient ways to evaluate the impact of body contour changes on the spatial dose distribution as well as knowing how sensitive the plans are to body contour changes.
In this study, we provide rules of thumb for dose percentage change and isodose line shift due to body contour changes for prostate and H&N VMAT plans. Our analysis is based on one-dimensional dose profile comparison and 3D gamma analysis. 
| MATERIALS AND METHODS

2.A | Patient population
2.B | VMAT treatment planning
For prostate plans, the CTV was defined as the prostate with or without proximal seminal vesicles; the planning target volume (PTV) was a 10 mm expansion of the CTV, 7 mm posteriorly. For the oropharyngeal plans, the high dose PTV and low dose PTV were created by a 3 mm uniform expansion of the corresponding CTVs but the PTVs were cropped 3 mm from skin.
All the clinical plans were made by the dosimetrists in the treatment planning system using the progressive resolution optimizer (Eclipse version 11.0, Varian Medical System, Palo Alto, CA) as per PROFIT trial protocol (60 Gy/20fractions), 13 departmental prostate protocol (78 Gy/39fractions), 14 and departmental H&N protocol 14 .
Each clinical plan had two to three full arcs with the energy of 6 MV and the anisotropic analytical algorithm with a dose grid resolution of 2.5 mm was used for dose calculation.
2.C | Body contour deformation
To create CT image sets with deformed body contours and to assess the theoretical impact of body contour changes, body contours in the p-CT were deformed using the margin tool in Eclipse Contouring for body contour shrinkage and expansion. For body contour expansion, the air gap between the original body and the new contour 
The body contour change may also lead to the shrinkage or expansion (shift) of clinically relevant isodose lines (lines connecting the voxels of equal dose), which may be a concern. For example, after body contour change, the 95% isodose line may not fully cover the PTV, leading to increased risk of loco-regional recurrence, or, a larger portion of the OARs may be covered by the high isodose lines, which may not be acceptable. Therefore, isodose line shift, the distance between the original isodose line and the isodose line on the new body of the same dose level (D), was evaluated:
Both dose percentage change and isodose line shift were acquired from the one-dimensional dose profiles, considering the balance of computational intensity with clinically relevant outcome.
For prostate patients, the dose profiles were chosen in the anterior-posterior direction through the CTV center-of-mass (COM) projection at three slices superior to the most inferior slice of the bladder. This slice was chosen because there were visible rectum, bladder, and prostate on this slice and the anterior-posterior direction is considered the most clinically relevant direction, which should reflect dose change to major OARs, namely rectum and bladder. The dose levels studied were 95%, 90%, 80%, 70%, and 60% (percent of prescription dose).
For H&N patients, four dose profiles were chosen: (a) Dose pro- The rules of thumb were the mean of the patients' medians for different dose levels for the same type of body contour change. | 117
2.D.1 | 3D gamma index
The gamma index is clinically used for quantitative evaluation of the treatment planning system calculated dose distribution and the measured dose distribution using the acceptability criteria. 17 In this study, for both prostate and H&N patients, a new structure In this study, 95% was chosen as the pass-fail threshold for gamma analysis. 
3.B | Rules of thumb for H&N plans
In Fig. 5 , for uniform body contour change, the medians of ΔD(%/ cm) had little variability and the variations of the medians were within 1%. Thus, it was reasonable to take the average of the medians as the rule of thumb (Table 1 ). This value (4%) was close to the reference value from single beam because the facial geometry was close to a cylinder and the body contour change was happening uniformly. However, the results from patients' shoulder position change had larger variations (as high as 6.5% or as low as 1.5%). This may be due to the fact that the original shoulder position on the p-CT varied tremendously between patients (the slice examined was five slices inferior to the most superior shoulder contour on the p-CT) and there may be shoulder contour variability.
In Fig. 6 One limitation of the rules of thumb for H&N plans is that these rules cannot assess the dosimetric effect in the buildup region (<1.5 cm from surface), where charged particle equilibrium is absent and the dose fall-off is very steep. In this region, the dose percentage and isodose line shift are highly dependent on the depth.
3.C | 3D gamma index
The results for the 3D gamma passing rate are shown in Table 2 .
For prostate plans, all the dose distributions on the deformed body with 1 cm body contour change at a single side had almost all the examined points agree with the original dose distribution with the criteria of 3 mm/3%; for 2 cm body contour change, more than 95% of the points passed the 3 mm/5% criteria. Additionally, when the body contour was deformed uniformly by 1 cm, the dose distributions passed or were close to pass the 95% threshold with the criteria of 3 mm/3%; while 2 cm uniform body
Boxplots of dose percentage change per centimeter body contour change, ΔD (%/cm), for 12 patients' 6 MV volumetric modulated arc therapy prostate plans. Four types of body contour changes and dose levels of 95%, 90%, 80%, 70%, and 60% in the anterior (A, blue boxplots) and posterior (P, red boxplots) directions relative to the prostate center-of-mass were examined. T A B L E 2 Mean three-dimensional (3D) gamma passing rate of the dose distributions on the deformed body and the original body for the same clinical volumetric modulated arc therapy (VMAT) plan with the criteria of 3 mm/3% and 3 mm/5%. The values in the brackets are the standard deviations. Mean 3D gamma passing rate less than 95% is in bold. Results are for 6 MV VMAT plans.
Prostate
Anterior body contour change (cm) Posterior body contour change (cm) F I G . 5. Boxplots of dose percentage change for every centimeter body contour change ΔD (%/cm) for 10 H&N patients' 6 MV volumetric modulated arc therapy plans. Two types of body contour changes (uniform body contour change and shoulder position change) and dose levels of 54, 48 Gy, 95%, 93%, and 78.9% were examined. Generally, With body contour expansion/shoulders moving superiorly, ΔD decreases; with body contour expansion/ shoulders moving inferiorly, ΔD increases.
Boxplots of isodose line shift per centimeter body contour change, ΔS (mm/cm), for 12 patients' 6 MV volumetric modulated arc therapy prostate plans, with the same parameters and definitions as Fig. 2 . With body contour expansion, the isodose lines get closer to prostate center of mass; with body contour shrinkage, isodose lines get further away from prostate center of mass.
| DISCUSSION
In this study, we find that prostate patients who have body contour changes less than 2 cm at a single side or less than 1 cm uniformly are unlikely to need further assessment. This corresponds to roughly 70% of the treatment fractions of prostate patients according to literature. Stanley et al. 3 reported that 34% of the 64 analyzed CBCT fractions from five patients showed a body contour change larger than 1 cm in any of the IMRT fields and the majority of the significant changes occurred in the anterior portion of the body contour, while Booth et al. 4 found that 68% of the 198 analyzed CBCT images from 19 patients were in the range of 0-1 cm, 28% 1-2 cm, and 4% > 2 cm with deviations occurring mostly in the postero-lateral direction.
For H&N patients, we find that a uniform body contour change less than 1 cm in facial area is unlikely to warrant further assessment due to dose change. However, the anatomical changes may cause the OARs (e.g., parotid glands) to enter high dose regions, which may not be acceptable even with less than 1 cm body contour change. There is evidence showing that weight loss is correlated with body contour changes. 16, 25 Weight loss for H&N patients is well-known 5-8 and body contour change due to weight loss has been quantified in some studies. Yang et al. 21 reported that the transverse diameter at the odontoid process level decreased on average by 4.6 mm from the first fraction to the 16th fraction and 7.9 mm from the first fraction to the 25th fraction for their 23 patients. Ahn et al. 25 showed that the average skin separation at the isocenter decreased by 3.2 mm at the 11th fraction, 7.5 mm at the 22nd fraction, and 14 mm at the 33rd fraction for the 23 patients. Tsai et al. 16 compared the p-CT with the 2nd CT acquired at the 22nd fraction for 38 H&N patients and they reported the separation distance in each slice of the CT images reduced by an average of 3.2-8.9 mm with the maximum reduction in 9 mm at the level of the 3rd cervical spine.
Moreover, we find that less than a 1 cm shoulder position change in the superior-inferior direction may not warrant plan reassessment, depending on institutional tolerance. This means the majority of the H&N patients do not need plan re-assessment due to shoulder position change if proper shoulder immobilization is used.
Neubauer et al. 9 conducted a study to assess the shoulder position variations for 10 H&N patients using 243 daily CT-on-rails scans and In this study, we evaluated the dosimetric effect of body contour changes and found the rules of thumb for dose percentage change and isodose line shift ( 26, 27 found that the PTV and CTV D99% were increased by 3%-4% and D30% for the rectum and bladder increased by 2%-4% per cm reduced depth. Pair et al. 24 showed that the target mean dose decreased or increased by 3%-4% per 1-cm SSD decrease or increase.
A similar study for H&N patients was implemented by Chen et al., (3%-4%) as those dosimetric parameters (e.g., CTV D99%, rectum and bladder D30%) mentioned above.
In this study, the rules of thumbs were derived from "controlled"
cases. However, in real clinical situations, the patients' body contour change may not be as regular. For cases like those, we can apply the idea of mean surface distance to approximate the equivalent uniform body contour change and then use the rules of thumb. Figure 7 shows In the future, daily online re-planning for prostate and H&N patients in a timely fashion may be achievable. However, currently, as a result of the limited resources in busy cancer centers, it is unlikely that daily online or offline re-planning will be applied to all patients on a routine basis. The decision on flagging the plans for further assessment and potentially re-planning is mostly based on the anatomical changes seen on the pre-treatment images (body contour change as the one that can be easily visualized). Thus, it is still essential to establish ballpark dosimetric consequences that result from body contour changes.
There are some limitations of this study. Firstly, 1D dose profile on a single slice was used for establishing the rules of thumb and a limited number of isodose lines were examined. As a result, the rules of thumb may not work well for low isodose lines (e.g., <50%). Overall, the rules of thumb tend to underestimate the low dose isodose line shift and overestimate the dose percentage change. This is because the dose gradient is shallow in the low dose region. Secondly, the body contour deformation may not accurately model real patient anatomical changes and not all the possible anatomical changes were modelled in this study. For example, the dosimetric effect due to tumor shrinkage for H&N patients was not evaluated because there were only two patients who had bulging tumors. Thus, cautions are needed in applying the rules of thumb under these circumstances. Moreover, although 3 mm/3% and 3 mm/5% are used in this study, which are the commonly used criteria for comparing treatment planning system calculated dose distributions with measured dose distributions, the specific criteria that are relevant for assessing the impact of body contour change may vary depending on the specific clinical scenario in question. To get an accurate estimation, a full dosimetric analysis of body contour changes is necessary. However, the rules of thumb developed in this manuscript can be useful to help the radiation oncologist/physicist/RT staff to make a quick decision on treat or not treat due to body contour changes while the patient is on bed, or to indicate the priority of the full dosimetric calculation, and as a "sanity check" when reviewing such calculations.
F I G . 7. Dose distributions on the planning computed tomography (p-CT) (a) and the synthetic CT (b, planning CT deformed to the conebeam CT on the 28th fraction). The body contour for the 28th fraction is marked on the planning CT (the orange contour) and there is significant body contour change on the left and posterior region. regions. In addition, guidelines were given for patients who underwent body contour changes but were unlikely to require plan reassessment. However, the judgment is dependent on center-specific tolerances for dose deviations.
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